Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2023

Open Access 01-12-2023 | Pulmonary Edema | Research

Clinical characteristics of venous thromboembolism onset from severe high altitude pulmonary edema in plateau regions

Authors: Yanmin Liu, Xinwei Feng, Yongxue Tang, Yanqiu Sun, Xiaoyan Pu, Xiaokai Feng

Published in: Thrombosis Journal | Issue 1/2023

Login to get access

Abstract

Background

To investigate venous thromboembolism (VTE) in hospitalized patients with severe high altitude pulmonary edema (HAPE), we performed a single center retrospective study to evaluate its clinical characteristics, prognosis, and potential thromboprophylaxis strategies in a large referral and treatment center in plateau regions.

Methods

We studied a total of 18 patients with severe HAPE from January 1, 2012 to December 31, 2021. Demographic and clinical data, laboratory data, including ultrasound scans of the lower extremities and cardiac ultrasound, and computed tomographic pulmonary angiography (CTPA) variables were obtained, and comparisons were made between groups with and without VTE.

Results

Of the 18 patients hospitalized with severe HAPE (age 43 (range, 34–54) years, 14 [77.8%] men), 7 patients developed VTE (38.9%), including 5 with deep vein thrombosis (DVT) and pulmonary embolism (PE), 2 of whom had DVT only. Eighteen patients are all firstly rapid ascent to high altitudes which the mean altitude was 3700 m (3656–4050 m). Compared with patients who did not have VTE, patients with VTE had a longer time in hospital (13 [11, 19] versus 9 [7, 12]; P = 0.027), respiratory failure (6 [85.7%] versus 2 [18.2%]; P = 0.013), the shortened APTT (21.50 [19.00, 27.50] versus 26.30 [24.80, 30.10]; P = 0.044) and the higher level of D-dimer (7.81 [4.62, 9.60] versus 2.90 [1.75, 3.37]; P = 0.003). The proportion of thromboprophylaxis is too low in our cohort which 2 of 18 (11.1%) patients were given VTE prophylaxis. There was no statistically significant difference between the VTE and non-VTE groups (0 [0.0%] versus 2 [18.2%]; P = 0.497).

Conclusions

The prevalence of VTE is high in hospitalized patients with severe high altitude pulmonary edema (HAPE). Prophylaxis for venous thromboembolism may be protective in severe HAPE patients after admission. Our data seem to suggest that VTE is probably an additional prognostic factors in patients with severe HAPE.
Literature
1.
Pennardt A. High-altitude pulmonary edema: diagnosis, prevention, and treatment. Curr Sports Med Rep. 2013;12(2):115–9.CrossRefPubMed
2.
Maggiorini M. Prevention and treatment of high-altitude pulmonary edema. Prog Cardiovasc Dis. 2010;52(6):500–6.CrossRefPubMed
3.
Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl):S495–501.CrossRefPubMed
4.
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4–8.PubMed
5.
Kumar DR, Hanlin E, Glurich I, Mazza JJ, Yale SH. Virchow's contribution to the understanding of thrombosis and cellular biology. Clin Med Res. 2010;8(3–4):168–72.CrossRefPubMedPubMedCentral
6.
7.
Moser KM, LeMoine JR, Nachtwey FJ, Spragg RG. Deep venous thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit. Jama. 1981;246(13):1422–4.CrossRefPubMed
8.
Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care. J Crit Care. 2002;17(2):95–104.CrossRefPubMed
9.
Wilasrusmee C, Kiranantawat K, Horsirimanont S, et al. Deep venous thrombosis in surgical intensive care unit: prevalence and risk factors. Asian J Surg. 2009;32(2):85–8.CrossRefPubMed
10.
Angral R, Islam MS, Kundan S. Incidence of deep vein thrombosis and justification of chemoprophylaxis in Indian patients: a prospective study. Bangladesh Med Res Counc Bull. 2012;38(2):67–71.CrossRefPubMed
11.
Dagadaki O, Birbas K, Mariolis T, Baltopoulos G, Myrianthefs P. Necessity of the periodical ultrasound assessment of the peripheral venous system in intensive care unit patients. Ultrasound Med Biol. 2019;45(2):367–73.CrossRefPubMed
12.
13.
Zhang C, Zhang Z, Mi J, et al. The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. Medicine. 2019;98(23):e15833.CrossRefPubMedPubMedCentral
14.
Alam P, Agarwal G, Kumar R, et al. Susceptibility to high-altitude pulmonary edema is associated with circulating miRNA levels under hypobaric hypoxia conditions. Am J Physiol Lung Cell Mole Physiol. 2020;319(2):L360–l8.CrossRef
15.
Kanipakam H, Sharma K, Thinlas T, Mohammad G, Pasha MAQ. Structural and functional alterations of nitric oxide synthase 3 due to missense variants associate with high-altitude pulmonary edema through dynamic study. J Biomol Struct Dyn. 2021;39(1):294–309.CrossRefPubMed
16.
Zong HF, Guo G, Liu J, Yang CZ, Bao LL. Influence of alveolar fluid on Aquaporins and Na+/K+-ATPase and its possible theoretical or clinical significance. Am J Perinatol. 2022;29(14):1586–95.CrossRefPubMed
17.
Li M, Tang X, Liao Z, et al. Hypoxia and low temperature up-regulate transferrin to induce hypercoagulability at high altitude. Blood. 2022;140(19):2063–75.
18.
Beristain-Covarrubias N, Perez-Toledo M, Thomas MR, Henderson IR, Watson SP, Cunningham AF. Understanding infection-induced thrombosis: lessons learned from animal models. Front Immunol. 2019;10:2569.CrossRefPubMedPubMedCentral
19.
Le Roux G, Larmignat P, Marchal M, Richalet JP. Haemostasis at high altitude. Int J Sports Med. 1992;13(Suppl 1):S49–51.CrossRefPubMed
20.
Pichler Hefti J, Risch L, Hefti U, et al. Changes of coagulation parameters during high altitude expedition. Swiss Med Wkly. 2010;140(7–8):111–7.PubMed
21.
Shang C, Wuren T, Ga Q, et al. The human platelet transcriptome and proteome is altered and pro-thrombotic functional responses are increased during prolonged hypoxia exposure at high altitude. Platelets. 2020;31(1):33–42.CrossRefPubMed
22.
Jha PK, Sahu A, Prabhakar A, et al. Genome-wide expression analysis suggests hypoxia-triggered hyper-coagulation leading to venous thrombosis at high altitude. Thromb Haemost. 2018;118(7):1279–95.CrossRefPubMed
23.
Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874–9.CrossRefPubMed
24.
Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med. 1999;341(11):793–800.CrossRefPubMed
25.
Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended Thromboprophylaxis with Betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534–44.CrossRefPubMed
26.
Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513–23.CrossRefPubMed
Metadata
Title
Clinical characteristics of venous thromboembolism onset from severe high altitude pulmonary edema in plateau regions
Authors
Yanmin Liu
Xinwei Feng
Yongxue Tang
Yanqiu Sun
Xiaoyan Pu
Xiaokai Feng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2023
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-023-00469-4

Other articles of this Issue 1/2023

Thrombosis Journal 1/2023 Go to the issue

Correspondence

Letter to editor – observation on the article titled “Vaccine-Induced Thrombotic Thrombocytopenia (VITT): first report from India”

Review

Addressing hypercoagulation in Cushing’s syndrome

Research

Extended use of dual antiplatelet therapy among older adults with acute coronary syndromes and associated variables: a cohort study

Research

A novel prognostic prediction indicator in patients with acute pulmonary embolism: Naples prognostic score

Research

Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy

Research

Factors associated with venous thromboembolic disease due to failed thromboprophylaxis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits